July 22 (Reuters) - Pfizer said on Wednesday the U.S. Food and Drug Administration has granted priority review to its ...

Men diagnosed with metastatic hormone-sensitive prostate cancer who carry a specific tumor deficiency now have a targeted treatment option after the FDA cleared capivasertib, sold as Truqap, for use ...

President Joe Biden recently gave an update on his treatment for metastatic prostate cancer. A urologist explains ways to ...

Clinicians report that early AKT inhibition side effects are manageable, allowing four out of five patients to maintain ...

Talzenna plus Xtandi is already approved in the U.S. to treat men with HRR gene-mutated metastatic castration-resistant prostate cancer. If approved, the expanded label would allow the therapy to be ...

Adding the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib to abiraterone acetate plus prednisone delayed disease progression and postponed the onset of symptoms in patients with metastatic ...

A comprehensive review of treatment options for patients with metastatic hormone-sensitive prostate cancer. Alicia Morgans, M.D., MPH: Metastatic hormone-sensitive prostate cancer is a particular type ...

Nubeqa (darolutamide) received FDA approval for metastatic castration-sensitive prostate cancer, showing significant improvement in radiographic progression-free survival. The ARANOTE trial involved ...

Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Let me introduce ...

A recent BMJ Oncology study screens the prevalence of prostate magnetic resonance imaging (MRI) lesions in men based on age rather than prostate-specific antigen (PSA) levels. Study: Prevalence of MRI ...